Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT03393962
PHASE1/PHASE2

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.

Official title: Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)

Key Details

Gender

FEMALE

Age Range

10 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-12-01

Completion Date

2028-12-31

Last Updated

2026-06-23

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

OC-EIEs

2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China